{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-021463","form_type":"8-K","ticker":"NSPR","cik":"0001433607","company_name":"InspireMD, Inc.","filed_at":"2024-05-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.394928+00:00","generated_at":"2026-06-01T07:57:09.455300+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"InspireMD C-GUARDIANS trial shows 1.95% primary endpoint event rate; PMA filing planned H2 2024","bullets":["Primary endpoint event rate of 1.95% through 12 months post-procedure, lowest reported for any carotid stent pivotal trial.","316 patients enrolled at 24 US/EU sites from July 2021 to June 2023; high-risk carotid endarterectomy patients.","Data to support PMA application to FDA in H2 2024; US launch of CGuard Prime anticipated H1 2025 if approved.","Results presented at LINC 2024 on May 28; investigator confirmed neuroprotective potential of MicroNet technology."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-021463","json":"https://secwatch.observer/filing/0001493152-24-021463.json","markdown":"https://secwatch.observer/filing/0001493152-24-021463.md","text":"https://secwatch.observer/filing/0001493152-24-021463.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1433607/000149315224021463/0001493152-24-021463-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1433607/000149315224021463/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T07:57:09.455300+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}